Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

357 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM).
Kröger N, Einsele H, Wolff D, Casper J, Freund M, Derigs G, Wandt H, Schäfer-Eckart K, Wittkowsky G, Schmitz N, Krüger W, Zabelina T, Renges H, Ayuk F, Krüll A, Zander A; German Study-group Multiple Myeloma (DSMM). Kröger N, et al. Bone Marrow Transplant. 2003 Jun;31(11):973-9. doi: 10.1038/sj.bmt.1704049. Bone Marrow Transplant. 2003. PMID: 12774047 Clinical Trial.
Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma.
Kröger N, Zagrivnaja M, Schwartz S, Badbaran A, Zabelina T, Lioznov M, Ayuk F, Zander A, Fehse B. Kröger N, et al. Exp Hematol. 2006 May;34(5):688-94. doi: 10.1016/j.exphem.2006.01.011. Exp Hematol. 2006. PMID: 16647575 Free article.
Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation.
Kröger N, Binder T, Zabelina T, Wolschke C, Schieder H, Renges H, Ayuk F, Dahlke J, Eiermann T, Zander A. Kröger N, et al. Transplantation. 2006 Oct 27;82(8):1024-30. doi: 10.1097/01.tp.0000235859.24513.43. Transplantation. 2006. PMID: 17060849
JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation.
Kröger N, Alchalby H, Klyuchnikov E, Badbaran A, Hildebrandt Y, Ayuk F, Bacher U, Bock O, Kvasnicka M, Fehse B, Zander A. Kröger N, et al. Blood. 2009 Feb 19;113(8):1866-8. doi: 10.1182/blood-2008-11-190975. Blood. 2009. PMID: 19228938 Free article. Clinical Trial. No abstract available.
Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma.
Kröger N, Badbaran A, Lioznov M, Schwarz S, Zeschke S, Hildebrand Y, Ayuk F, Atanackovic D, Schilling G, Zabelina T, Bacher U, Klyuchnikov E, Shimoni A, Nagler A, Corradini P, Fehse B, Zander A. Kröger N, et al. Exp Hematol. 2009 Jul;37(7):791-8. doi: 10.1016/j.exphem.2009.03.008. Epub 2009 May 31. Exp Hematol. 2009. PMID: 19487069 Free article.
357 results